BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Primo Biotechnology Secures PIC/S GMP and GDP Certifications, Strengthening Global Position in Nuclear Medicine

Primo Biotechnology Co., Ltd. ("Primo") proudly announces that its Taoyuan pharmaceutical facility has successfully passed inspection by Taiwan Food and Dr...

April 25, 2025 | News

Senhwa’s CX-4945 Shows Promising Disease Control and Durability in Refractory Basal Cell Carcinoma

Basal Cell Carcinoma CSR Highlights CX-4945 Monotherapy: Progression-free survival (PFS) exceeded 21 months in two patients. Optimal Treatment Res...

April 03, 2025 | News

TCI Biotech Elevates CDMO+ Services with US-Based Glass Bottling for Liquid Supplements

TCI Biotech (TCI Co., Ltd.), a CDMO+ organization specializing in health and wellness products, is spotlighting its comprehensive US-based glass bottling s...

April 03, 2025 | News

AnHorn Medicines Doses First Subject in U.S. Phase I Trial for AH-001, a First-in-Class Protein Degrader Targeting Hair Loss

AnHorn Medicines, a pioneering AI-driven new drug discovery company, is pleased to announce that, AH-001, a first-in-class protein degrader for androg...

March 27, 2025 | News

TPIsoftware & Yuan's General Hospital Transform Healthcare with GenAI Platform

TPIsoftware (TWSE: 7781) and Yuan's General Hospital, a leading medical institution in Southern Taiwan, have collaborated to launch a digit...

March 20, 2025 | News

Formosa Pharmaceuticals and Cipla Sign Multi-Regional Licensing Deal for Ophthalmic Suspension APP13007

Taiwan-based Formosa Pharmaceuticals announced an exclusive licensing agreement with Cipla Limited referred to as "Cipla" for the commercialization of clob...

March 19, 2025 | News

Taiwan’s TCI Biotech Reports Strong 2024 Financial Results, Driving Innovation and Global Expansion

TCI Biotech, a leading CDMO+ innovator in health food and skincare biotechnology, has released its consolidated financial results for the fiscal year endin...

March 11, 2025 | Company results

Health2Sync Secures Over $20M in Series C Funding to Drive Global Expansion and AI-Driven Chronic Disease Management

Health2Sync (H2), a leading digital health company specializing in chronic disease management, today announced it has raised over US$20 million in a Series...

March 05, 2025 | News

TAHO Pharmaceuticals’ Apixaban Oral Dissolving Film Shows Positive Results in Pivotal Study

TAHO Pharmaceuticals announces positive preliminary results from the pivotal study of TAH3311, the world's first Apixaban oral dissolving film (ODF). The s...

February 18, 2025 | News

XPOVIO® Secures Approval in Taiwan as First XPO1 Inhibitor for Relapsed/Refractory Multiple Myeloma

XPOVIO® is the first XPO1 inhibitor approved in Taiwan for the treatment of adult patients with relapsed/refractory multiple...

February 14, 2025 | News

Taiwan's Caliway Biopharmaceuticals Reports Groundbreaking Results for CBL-514 in U.S. and Canada Phase 2b Study

Caliway Biopharmaceuticals unveiled the impressive results of its second Phase 2b clinical study (CBL-0205) for CBL-514, the world’s first in...

February 11, 2025 | News

CMU and Healthcare System Showcase AI-Driven Breakthroughs in Cancer Therapy and Drug Discovery at Healthcare Expo Taiwan

China Medical University (CMU) and Healthcare System showcased groundbreaking advancements in AI-driven drug discovery and cancer therapy at the 8t...

February 06, 2025 | Report

Taiwan’s JelloX Biotech Pioneers AI-Powered 3D Pathology for Patient-Centered Cancer Care

JelloX Biotech Inc., a Taiwan-based startup focused on cancer pathology, is unveiling its vision for AI and 3D digital pathology to advance...

January 23, 2025 | News

TAHO Pharmaceuticals Completes Pivotal Trial for World’s First Anticoagulant Oral Dissolving Film

TAHO Pharmaceuticals is pleased to announce the successful completion of the pivotal trial for TAH3311, the first anticoagulant oral dissolving film (ODF)....

January 22, 2025 | News

Stay Connected